[vc_row full_width=”stretch_row” content_placement=”middle” el_class=”top-section-one” css=”.vc_custom_1604683363040{background-image: url(https://blog.patentrack.com/wp-content/uploads/2020/10/cooleygo-page-header-11b.jpg?id=149) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column][vc_column_text el_class=”cst-guidence”]

TRENDS

We’re always listening. Read about what’s trending now.

[/vc_column_text][/vc_column][/vc_row][vc_row el_id=”q2-twenty”][vc_column][vc_column_text]

Q2 2020 – Navigating Through the Storm

The second quarter of 2020 represented the first complete quarter of private financings during the COVID-19 pandemic. Despite the multiple economic impacts of the crisis, our data showed resilience in the volume and valuations of deals completed. In Q2 2020, Cooley handled 304 disclosable deals representing more than $9.8 billion of invested capital. Both deal volumes and aggregate dollars raised decreased in June from April and May levels, a possible preview of future trends. Median pre-money valuations held steady in Q2 across deal stages, though we did see a decrease in valuations for seed transactions.

Surprisingly, deal terms during the quarter showed no significant shift toward an investor-friendly environment. While we did see a small uptick in preference multiples, just 5% of transactions had full participating liquidation preferences in Q2. Additionally, the percentage of deals utilizing pay-to-play provisions decreased from the prior quarter. Tracking these deal term trends in future quarters will be key to understanding the true impact of COVID-19 on the overall financing environment.

Industry spotlight: trends in life sciences

Following a surge in deal volume during the month of March, Cooley handled 64 life sciences-focused deals in Q2 2020, up 13% in volume over the same time period last year. Half of the deals were focused on earlier stage companies raising A and B rounds, an indication of continued investor appetite for new innovation in the sector. Aggregate deal value across all round types was $2.24 billion, a 43% surge from the same time period last year. To view more details on life sciences trends, use the “Life sciences” filter in our interactive data visualization.

Industry spotlight: trends in technology

After a very strong March, Cooley handled 172 technology sector deals in Q2 2020, representing $5.22 billion in aggregate deal value and a 42% uptick in deal volume over the same period in 2019. Seed, Series A and Series B rounds accounted for 70% of deals this quarter. From April to June, we saw a drop in both deal value and aggregate dollars raised, reflecting our broader data set for the same period. To view more details on technology deal trends, use the “Technology” filter in our interactive data visualization.

[/vc_column_text][/vc_column][/vc_row][vc_row el_id=”bottom-buttons”][vc_column][vc_column_text el_class=”cst-more-text”]

MORE FROM COOLEY GO

[/vc_column_text][vc_row_inner][vc_column_inner width=”1/2″][vc_raw_html el_class=”cst-links-inner”]JTNDZGl2JTIwaWQlM0QlMjJmaXJzdC1jdXN0b20lMjIlM0UlMEElM0NhJTIwaHJlZiUzRCUyMiUyMyUyMiUzRSUzQ2klM0VHdWlkYW5jZSUzQyUyRmklM0UlM0MlMkZhJTNFJTBBJTNDJTJGZGl2JTNF[/vc_raw_html][/vc_column_inner][vc_column_inner width=”1/2″][vc_raw_html el_class=”cst-links-inner”]JTNDZGl2JTIwaWQlM0QlMjJmaXJzdC1jdXN0b20lMjIlM0UlMEElM0NhJTIwaHJlZiUzRCUyMiUyMyUyMiUzRSUzQ2klM0VEb2N1bWVudHMlM0MlMkZpJTNFJTNDJTJGYSUzRSUwQSUzQyUyRmRpdiUzRQ==[/vc_raw_html][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]